Bryan Cave Leighton Paisner advises Teva on sale of a Yarsolavl pharmaceutical plant to R-Pharm Group
Bryan Cave Leighton Paisner, formerly Goltsblat BLP in Russia, has advised Teva on selling a pharmaceutical plant in Yaroslavl Industrial Park (Novosyolki) to R-Pharm Group. The GMP-certified enterprise located on 19 hectares offers 13,000 sq.m. of production space. It manufactures medications for cardiological, neurological and endocrinological diseases.
The terms of the sale transaction include a five-year agreement under which R-Pharm will act as Teva’s production partner in order to ensure continuous access for patients to Teva medicines.
The BCLP Russia team led by Partners Vitaly Mozharowski (Real Estate and Construction) and Matvey Kaploukhiy (Corporate / M&A) included: Oksana Orlovskaya, Counsel, Corporate / M&A, Inna Firsova, Counsel, Real Estate and Construction, Vladislav Vdovin, Head of Commercial, Mikhail Erokhin, Associate, Corporate / M&A, Elena Naumova, Junior Associate, Corporate / M&A and others.
This document provides a general summary and is for information/educational purposes only. It is not intended to be comprehensive, nor does it constitute legal advice. Specific legal advice should always be sought before taking or refraining from taking any action.